Research ArticleArticle
Patients with Rheumatoid Arthritis in the Australian OPAL Cohort Show Significant Improvement in Disease Activity over 5 Years: A Multicenter Observational Study
Geoffrey Littlejohn, Lynden Roberts, Paul Bird, Julien de Jager, Hedley Griffiths, Dave Nicholls, Jennifer Young, Jane Zochling and Kathleen E. Tymms
The Journal of Rheumatology July 2015, jrheum.141575; DOI: https://doi.org/10.3899/jrheum.141575
Geoffrey Littlejohn
From Monash University, Clayton; James Cook University, Douglas; Combined Rheumatology Practice, Sydney; Gold Coast Rheumatology, Southport; Barwon Rheumatology Service, Geelong; Coast Joint Care, Maroochydore; Roche Products Propriety Limited, Dee Why; Menzies Research Institute Tasmania, Hobart; Canberra Rheumatology, Canberra, Australia. The OPAL-QUMI (Optimising Patient outcome in Australian RheumatoLogy-Quality Use of Medicines Initiative) is supported by Roche Products Propriety Limited (Australia), the sponsor of this study. G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash University; L. Roberts, MBBS, PhD, FRACP, Associate Professor of Medicine, Monash University and James Cook University; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; J. de Jager, MBBS, FRACP, Professor of Medicine, Gold Coast Rheumatology; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; J. Young, PhD, Medical Manager, Roche Products Propriety Limited; J. Zochling, MBBS, FRACP, MMed (ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; K.E. Tymms, MBBS, FRACP, Associate Professor of Medicine, Canberra Rheumatology. Address correspondence to Professor G. Littlejohn, Monash University, 246 Clayton Road, Clayton, VIC, 3168, Australia. E-mail: geoff.littlejohn@monash.edu. Accepted for publication April 29, 2015.
Lynden Roberts
From Monash University, Clayton; James Cook University, Douglas; Combined Rheumatology Practice, Sydney; Gold Coast Rheumatology, Southport; Barwon Rheumatology Service, Geelong; Coast Joint Care, Maroochydore; Roche Products Propriety Limited, Dee Why; Menzies Research Institute Tasmania, Hobart; Canberra Rheumatology, Canberra, Australia. The OPAL-QUMI (Optimising Patient outcome in Australian RheumatoLogy-Quality Use of Medicines Initiative) is supported by Roche Products Propriety Limited (Australia), the sponsor of this study. G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash University; L. Roberts, MBBS, PhD, FRACP, Associate Professor of Medicine, Monash University and James Cook University; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; J. de Jager, MBBS, FRACP, Professor of Medicine, Gold Coast Rheumatology; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; J. Young, PhD, Medical Manager, Roche Products Propriety Limited; J. Zochling, MBBS, FRACP, MMed (ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; K.E. Tymms, MBBS, FRACP, Associate Professor of Medicine, Canberra Rheumatology. Address correspondence to Professor G. Littlejohn, Monash University, 246 Clayton Road, Clayton, VIC, 3168, Australia. E-mail: geoff.littlejohn@monash.edu. Accepted for publication April 29, 2015.
Paul Bird
From Monash University, Clayton; James Cook University, Douglas; Combined Rheumatology Practice, Sydney; Gold Coast Rheumatology, Southport; Barwon Rheumatology Service, Geelong; Coast Joint Care, Maroochydore; Roche Products Propriety Limited, Dee Why; Menzies Research Institute Tasmania, Hobart; Canberra Rheumatology, Canberra, Australia. The OPAL-QUMI (Optimising Patient outcome in Australian RheumatoLogy-Quality Use of Medicines Initiative) is supported by Roche Products Propriety Limited (Australia), the sponsor of this study. G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash University; L. Roberts, MBBS, PhD, FRACP, Associate Professor of Medicine, Monash University and James Cook University; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; J. de Jager, MBBS, FRACP, Professor of Medicine, Gold Coast Rheumatology; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; J. Young, PhD, Medical Manager, Roche Products Propriety Limited; J. Zochling, MBBS, FRACP, MMed (ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; K.E. Tymms, MBBS, FRACP, Associate Professor of Medicine, Canberra Rheumatology. Address correspondence to Professor G. Littlejohn, Monash University, 246 Clayton Road, Clayton, VIC, 3168, Australia. E-mail: geoff.littlejohn@monash.edu. Accepted for publication April 29, 2015.
Julien de Jager
From Monash University, Clayton; James Cook University, Douglas; Combined Rheumatology Practice, Sydney; Gold Coast Rheumatology, Southport; Barwon Rheumatology Service, Geelong; Coast Joint Care, Maroochydore; Roche Products Propriety Limited, Dee Why; Menzies Research Institute Tasmania, Hobart; Canberra Rheumatology, Canberra, Australia. The OPAL-QUMI (Optimising Patient outcome in Australian RheumatoLogy-Quality Use of Medicines Initiative) is supported by Roche Products Propriety Limited (Australia), the sponsor of this study. G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash University; L. Roberts, MBBS, PhD, FRACP, Associate Professor of Medicine, Monash University and James Cook University; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; J. de Jager, MBBS, FRACP, Professor of Medicine, Gold Coast Rheumatology; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; J. Young, PhD, Medical Manager, Roche Products Propriety Limited; J. Zochling, MBBS, FRACP, MMed (ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; K.E. Tymms, MBBS, FRACP, Associate Professor of Medicine, Canberra Rheumatology. Address correspondence to Professor G. Littlejohn, Monash University, 246 Clayton Road, Clayton, VIC, 3168, Australia. E-mail: geoff.littlejohn@monash.edu. Accepted for publication April 29, 2015.
Hedley Griffiths
From Monash University, Clayton; James Cook University, Douglas; Combined Rheumatology Practice, Sydney; Gold Coast Rheumatology, Southport; Barwon Rheumatology Service, Geelong; Coast Joint Care, Maroochydore; Roche Products Propriety Limited, Dee Why; Menzies Research Institute Tasmania, Hobart; Canberra Rheumatology, Canberra, Australia. The OPAL-QUMI (Optimising Patient outcome in Australian RheumatoLogy-Quality Use of Medicines Initiative) is supported by Roche Products Propriety Limited (Australia), the sponsor of this study. G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash University; L. Roberts, MBBS, PhD, FRACP, Associate Professor of Medicine, Monash University and James Cook University; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; J. de Jager, MBBS, FRACP, Professor of Medicine, Gold Coast Rheumatology; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; J. Young, PhD, Medical Manager, Roche Products Propriety Limited; J. Zochling, MBBS, FRACP, MMed (ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; K.E. Tymms, MBBS, FRACP, Associate Professor of Medicine, Canberra Rheumatology. Address correspondence to Professor G. Littlejohn, Monash University, 246 Clayton Road, Clayton, VIC, 3168, Australia. E-mail: geoff.littlejohn@monash.edu. Accepted for publication April 29, 2015.
Dave Nicholls
From Monash University, Clayton; James Cook University, Douglas; Combined Rheumatology Practice, Sydney; Gold Coast Rheumatology, Southport; Barwon Rheumatology Service, Geelong; Coast Joint Care, Maroochydore; Roche Products Propriety Limited, Dee Why; Menzies Research Institute Tasmania, Hobart; Canberra Rheumatology, Canberra, Australia. The OPAL-QUMI (Optimising Patient outcome in Australian RheumatoLogy-Quality Use of Medicines Initiative) is supported by Roche Products Propriety Limited (Australia), the sponsor of this study. G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash University; L. Roberts, MBBS, PhD, FRACP, Associate Professor of Medicine, Monash University and James Cook University; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; J. de Jager, MBBS, FRACP, Professor of Medicine, Gold Coast Rheumatology; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; J. Young, PhD, Medical Manager, Roche Products Propriety Limited; J. Zochling, MBBS, FRACP, MMed (ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; K.E. Tymms, MBBS, FRACP, Associate Professor of Medicine, Canberra Rheumatology. Address correspondence to Professor G. Littlejohn, Monash University, 246 Clayton Road, Clayton, VIC, 3168, Australia. E-mail: geoff.littlejohn@monash.edu. Accepted for publication April 29, 2015.
Jennifer Young
From Monash University, Clayton; James Cook University, Douglas; Combined Rheumatology Practice, Sydney; Gold Coast Rheumatology, Southport; Barwon Rheumatology Service, Geelong; Coast Joint Care, Maroochydore; Roche Products Propriety Limited, Dee Why; Menzies Research Institute Tasmania, Hobart; Canberra Rheumatology, Canberra, Australia. The OPAL-QUMI (Optimising Patient outcome in Australian RheumatoLogy-Quality Use of Medicines Initiative) is supported by Roche Products Propriety Limited (Australia), the sponsor of this study. G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash University; L. Roberts, MBBS, PhD, FRACP, Associate Professor of Medicine, Monash University and James Cook University; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; J. de Jager, MBBS, FRACP, Professor of Medicine, Gold Coast Rheumatology; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; J. Young, PhD, Medical Manager, Roche Products Propriety Limited; J. Zochling, MBBS, FRACP, MMed (ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; K.E. Tymms, MBBS, FRACP, Associate Professor of Medicine, Canberra Rheumatology. Address correspondence to Professor G. Littlejohn, Monash University, 246 Clayton Road, Clayton, VIC, 3168, Australia. E-mail: geoff.littlejohn@monash.edu. Accepted for publication April 29, 2015.
Jane Zochling
From Monash University, Clayton; James Cook University, Douglas; Combined Rheumatology Practice, Sydney; Gold Coast Rheumatology, Southport; Barwon Rheumatology Service, Geelong; Coast Joint Care, Maroochydore; Roche Products Propriety Limited, Dee Why; Menzies Research Institute Tasmania, Hobart; Canberra Rheumatology, Canberra, Australia. The OPAL-QUMI (Optimising Patient outcome in Australian RheumatoLogy-Quality Use of Medicines Initiative) is supported by Roche Products Propriety Limited (Australia), the sponsor of this study. G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash University; L. Roberts, MBBS, PhD, FRACP, Associate Professor of Medicine, Monash University and James Cook University; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; J. de Jager, MBBS, FRACP, Professor of Medicine, Gold Coast Rheumatology; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; J. Young, PhD, Medical Manager, Roche Products Propriety Limited; J. Zochling, MBBS, FRACP, MMed (ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; K.E. Tymms, MBBS, FRACP, Associate Professor of Medicine, Canberra Rheumatology. Address correspondence to Professor G. Littlejohn, Monash University, 246 Clayton Road, Clayton, VIC, 3168, Australia. E-mail: geoff.littlejohn@monash.edu. Accepted for publication April 29, 2015.
Kathleen E. Tymms
From Monash University, Clayton; James Cook University, Douglas; Combined Rheumatology Practice, Sydney; Gold Coast Rheumatology, Southport; Barwon Rheumatology Service, Geelong; Coast Joint Care, Maroochydore; Roche Products Propriety Limited, Dee Why; Menzies Research Institute Tasmania, Hobart; Canberra Rheumatology, Canberra, Australia. The OPAL-QUMI (Optimising Patient outcome in Australian RheumatoLogy-Quality Use of Medicines Initiative) is supported by Roche Products Propriety Limited (Australia), the sponsor of this study. G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash University; L. Roberts, MBBS, PhD, FRACP, Associate Professor of Medicine, Monash University and James Cook University; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; J. de Jager, MBBS, FRACP, Professor of Medicine, Gold Coast Rheumatology; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; J. Young, PhD, Medical Manager, Roche Products Propriety Limited; J. Zochling, MBBS, FRACP, MMed (ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; K.E. Tymms, MBBS, FRACP, Associate Professor of Medicine, Canberra Rheumatology. Address correspondence to Professor G. Littlejohn, Monash University, 246 Clayton Road, Clayton, VIC, 3168, Australia. E-mail: geoff.littlejohn@monash.edu. Accepted for publication April 29, 2015.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Patients with Rheumatoid Arthritis in the Australian OPAL Cohort Show Significant Improvement in Disease Activity over 5 Years: A Multicenter Observational Study
Geoffrey Littlejohn, Lynden Roberts, Paul Bird, Julien de Jager, Hedley Griffiths, Dave Nicholls, Jennifer Young, Jane Zochling, Kathleen E. Tymms
The Journal of Rheumatology Jul 2015, jrheum.141575; DOI: 10.3899/jrheum.141575
Patients with Rheumatoid Arthritis in the Australian OPAL Cohort Show Significant Improvement in Disease Activity over 5 Years: A Multicenter Observational Study
Geoffrey Littlejohn, Lynden Roberts, Paul Bird, Julien de Jager, Hedley Griffiths, Dave Nicholls, Jennifer Young, Jane Zochling, Kathleen E. Tymms
The Journal of Rheumatology Jul 2015, jrheum.141575; DOI: 10.3899/jrheum.141575